CZ20012544A3 - Farmaceutické balení - Google Patents

Farmaceutické balení Download PDF

Info

Publication number
CZ20012544A3
CZ20012544A3 CZ20012544A CZ20012544A CZ20012544A3 CZ 20012544 A3 CZ20012544 A3 CZ 20012544A3 CZ 20012544 A CZ20012544 A CZ 20012544A CZ 20012544 A CZ20012544 A CZ 20012544A CZ 20012544 A3 CZ20012544 A3 CZ 20012544A3
Authority
CZ
Czechia
Prior art keywords
hepatitis
pharmaceutical package
virus
package according
vaccine
Prior art date
Application number
CZ20012544A
Other languages
Czech (cs)
English (en)
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G. Vandepapeliere
Martine Anne Cecile Wettendorff
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of CZ20012544A3 publication Critical patent/CZ20012544A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20012544A 1999-01-12 1999-12-21 Farmaceutické balení CZ20012544A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
CZ20012544A3 true CZ20012544A3 (cs) 2002-01-16

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012544A CZ20012544A3 (cs) 1999-01-12 1999-12-21 Farmaceutické balení

Country Status (19)

Country Link
EP (1) EP1140163A2 (ja)
JP (1) JP2002534438A (ja)
KR (1) KR20010090011A (ja)
CN (1) CN1391482A (ja)
AR (1) AR022250A1 (ja)
AU (1) AU760574B2 (ja)
BR (1) BR9916893A (ja)
CA (1) CA2359110A1 (ja)
CO (1) CO5241355A1 (ja)
CZ (1) CZ20012544A3 (ja)
HK (1) HK1041434A1 (ja)
HU (1) HUP0105070A2 (ja)
IL (1) IL144186A0 (ja)
NO (1) NO20013337L (ja)
NZ (1) NZ512890A (ja)
PL (1) PL349347A1 (ja)
TR (1) TR200102024T2 (ja)
WO (1) WO2000041463A2 (ja)
ZA (1) ZA200105690B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
ATE383375T1 (de) 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
WO2003028758A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
EP3903815A4 (en) * 2018-12-24 2022-09-28 Grand Theravac Life Science (Nanjing) Co., Ltd. PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEPATITIS B, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
EP4321173A1 (en) * 2021-04-07 2024-02-14 Denka Company Limited Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
EP1064025B1 (en) * 1998-03-09 2006-09-13 GlaxoSmithKline Biologicals S.A. Combined vaccine compositions

Also Published As

Publication number Publication date
NO20013337L (no) 2001-08-17
CA2359110A1 (en) 2000-07-20
PL349347A1 (en) 2002-07-15
HUP0105070A2 (hu) 2002-04-29
CO5241355A1 (es) 2003-01-31
CN1391482A (zh) 2003-01-15
TR200102024T2 (tr) 2001-12-21
JP2002534438A (ja) 2002-10-15
EP1140163A2 (en) 2001-10-10
NZ512890A (en) 2003-09-26
BR9916893A (pt) 2001-11-20
WO2000041463A3 (en) 2000-11-09
IL144186A0 (en) 2002-05-23
HK1041434A1 (zh) 2002-07-12
AU760574B2 (en) 2003-05-15
ZA200105690B (en) 2002-09-25
AU2100900A (en) 2000-08-01
KR20010090011A (ko) 2001-10-17
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (en) 2000-07-20
AR022250A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
EP2247605B1 (en) Hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors
CZ20012544A3 (cs) Farmaceutické balení
AU2021200857B2 (en) Crystalline forms of tenofovir alafenamide
US9878035B2 (en) Hepatitis B vaccine
CZ337997A3 (cs) Prostředek s vakcinačním účinkem a jeho použití pro výrobu vakciny
JP2018512428A5 (ja)
WO2015196935A1 (zh) 含有CpG寡核苷酸的药物组合物
JP2023506439A (ja) 医薬組成物及びその用途
KR20220119616A (ko) Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법
EP1284720B1 (en) L-fmau for the treatment of hepatitis delta viral infection
KR20070110513A (ko) 알루미늄 포스페이트 및 3ｄ－ｍｐｌ을 포함하는 보조약조성물
US20110059132A1 (en) Composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
WO2003037265A2 (en) Method of treating viral infections
KR20210151047A (ko) B형 간염 치료를 위한 면역원성 조성물
TW201735945A (zh) 包括b型肝炎病毒之表面及核殼體抗原的藥學組成物
MXPA01007112A (en) Novel treatment
JP2022516041A (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
US7144703B2 (en) Composition
CN113058033B (zh) 一种用于预防和治疗乙型肝炎的药物组合物及其用途
KR20120125253A (ko) Ｂ형 간염 바이러스 감염 치료용 조성물 및 치료방법
TWI311563B (en) Method for production a stable,immunogenic hepatitis b vaccine without trace of thiomersal
NZ705184B2 (en) Yeast-based therapeutic for chronic hepatitis b infection